{"product_id":"biomarin-business-model-canvas","title":"BioMarin Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin's Biotech Blueprint: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover the strategic brilliance behind BioMarin Pharmaceutical’s success with our comprehensive Business Model Canvas. This detailed analysis breaks down how they serve rare disease patients, forge critical partnerships, and generate revenue through innovative therapies. Ideal for anyone seeking to understand the intricacies of a leading biotech firm.\u003c\/p\u003e\n\u003cp\u003eDive into the complete Business Model Canvas for BioMarin Pharmaceutical and gain unparalleled insight into their patient-centric approach and R\u0026amp;D engine. See how they manage costs and create value in the specialized biotech market. Download the full, editable version to fuel your own strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances for Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin actively pursues strategic alliances with leading academic institutions, renowned research organizations, and other innovative biotechnology firms. These collaborations are crucial for advancing its pipeline of therapies targeting rare genetic diseases.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are designed to leverage specialized expertise and cutting-edge technology, which significantly accelerates the discovery and development phases for novel treatments. For instance, in 2024, BioMarin continued its collaborations with several university research labs focused on gene therapy delivery mechanisms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-development and Commercialization Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin actively engages in co-development and commercialization agreements with other pharmaceutical companies. A prime example is its enduring partnership with Genzyme, a subsidiary of Sanofi, for Aldurazyme. This collaboration highlights the strategic advantage of sharing development burdens and leveraging specialized commercialization expertise.\u003c\/p\u003e\n\u003cp\u003eThese alliances are crucial for expanding market reach and mitigating the significant financial risks associated with drug development. By pooling resources and capabilities, BioMarin can accelerate the path to market for its innovative therapies, as seen in the successful commercialization of products like Aldurazyme.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Foundations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin actively partners with patient advocacy groups and foundations focused on rare genetic diseases. These collaborations are vital for gaining deep insights into patient experiences and needs, ensuring these perspectives shape their drug development processes. For instance, the company's engagement with groups like the National Organization for Rare Disorders (NORD) helps inform clinical trial design and patient support programs, reflecting a commitment to patient-centric innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Clinical Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin's collaborations with healthcare providers are fundamental for the successful execution of clinical trials and the ongoing management of its specialized therapies. These partnerships are crucial for gathering robust real-world evidence, which helps validate the long-term efficacy and safety of their treatments. For instance, in 2024, BioMarin continued to leverage its network of specialized treatment centers to enroll patients in ongoing trials for conditions like phenylketonuria (PKU) and hemophilia.\u003c\/p\u003e\n\u003cp\u003eClinical Research Organizations (CROs) play an equally vital role, providing the expertise and infrastructure necessary to navigate the complex landscape of drug development and regulatory approval. These partnerships streamline the process of data collection, analysis, and reporting, ensuring compliance with stringent industry standards. BioMarin's engagement with CROs in 2024 was instrumental in advancing its pipeline candidates through various phases of clinical testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trials:\u003c\/strong\u003e Partnerships enable BioMarin to conduct essential clinical trials, a cornerstone of drug development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReal-World Evidence (RWE):\u003c\/strong\u003e Collaborations with healthcare providers facilitate the collection of RWE, supporting post-market surveillance and value-based assessments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access and Monitoring:\u003c\/strong\u003e These relationships ensure appropriate administration and monitoring of BioMarin's therapies, enhancing patient outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Compliance:\u003c\/strong\u003e CROs assist in navigating regulatory pathways, ensuring adherence to global standards for clinical research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacies and Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin leverages strategic alliances with specialty pharmacies and robust global distribution networks to ensure its rare disease therapies reach patients worldwide. This critical partnership allows for the efficient and safe delivery of complex, often temperature-controlled, medications across numerous international markets.  For instance, in 2024, BioMarin's commitment to expanding access meant navigating intricate regulatory landscapes and supply chains in over 50 countries.\u003c\/p\u003e\n\u003cp\u003eThese collaborations are vital for managing the logistics of BioMarin's high-cost, low-volume treatments. They ensure that patients, often in remote locations, receive their life-changing therapies without interruption. This focus on specialized distribution is a cornerstone of BioMarin's business model, directly supporting its mission to serve underserved patient populations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialty Pharmacy Integration:\u003c\/strong\u003e BioMarin works closely with pharmacies equipped to handle the specific storage, dispensing, and patient support requirements of its advanced therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Distribution Hubs:\u003c\/strong\u003e Partnerships with established logistics providers ensure temperature-controlled transport and timely delivery across diverse geographical regions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Support Services:\u003c\/strong\u003e These networks often extend to providing crucial patient education and adherence programs, enhancing treatment outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Compliance:\u003c\/strong\u003e Collaborations ensure adherence to varying international regulations for pharmaceutical distribution and import\/export.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Innovation and Patient Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin's key partnerships extend to academic institutions and research organizations, vital for early-stage discovery and gene therapy advancements, as evidenced by ongoing 2024 collaborations with university labs focused on delivery mechanisms.\u003c\/p\u003e\n\u003cp\u003eCo-development and commercialization alliances, such as the long-standing one with Genzyme for Aldurazyme, are crucial for sharing development costs and leveraging commercial expertise, a strategy that continues to be a pillar of their market access strategy.\u003c\/p\u003e\n\u003cp\u003eEngaging with patient advocacy groups like NORD in 2024 provides invaluable patient insights, directly informing clinical trial design and support programs, underscoring BioMarin's patient-centric approach.\u003c\/p\u003e\n\u003cp\u003ePartnerships with healthcare providers and CROs are essential for robust clinical trial execution, real-world evidence gathering, and navigating complex regulatory pathways, with CRO engagement in 2024 being instrumental in advancing pipeline candidates.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBioMarin's business model focuses on developing and commercializing innovative therapies for rare genetic diseases, targeting a specific patient population with high unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes strong R\u0026amp;D capabilities, strategic partnerships, and a patient-centric approach to deliver life-changing treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBioMarin’s Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their strategy for developing and commercializing orphan drugs, simplifying complex processes for stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Novel Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin's central mission revolves around substantial investment in research and development to pioneer novel therapies. This commitment spans enzyme replacement therapies, protein therapeutics, and cutting-edge gene therapies, all aimed at addressing serious and often life-threatening rare genetic diseases.\u003c\/p\u003e\n\u003cp\u003eThe company actively progresses its pipeline, with promising candidates like BMN 351 for Duchenne Muscular Dystrophy and BMN 333 for skeletal conditions demonstrating this dedication. For instance, as of early 2024, BioMarin reported approximately $650 million in R\u0026amp;D expenses for the first quarter, underscoring the significant resources allocated to this crucial activity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA core activity involves meticulously conducting clinical trials to evaluate the safety and effectiveness of novel drug candidates, a process essential for bringing new treatments to patients.\u003c\/p\u003e\n\u003cp\u003eFollowing successful trials, BioMarin focuses on preparing and submitting extensive regulatory applications to health authorities worldwide, aiming to secure marketing approvals for its therapies.\u003c\/p\u003e\n\u003cp\u003eFor instance, BioMarin is targeting submissions in the latter half of 2025 to broaden PALYNZIQ's age eligibility in both the United States and Europe, demonstrating ongoing efforts in regulatory advancement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin’s manufacturing strategy involves a hybrid approach, utilizing its own facilities in California and Ireland for producing certain therapies. This in-house capability allows for direct control over quality and production processes for key products.\u003c\/p\u003e\n\u003cp\u003eComplementing its internal manufacturing, BioMarin also relies on contract manufacturing organizations (CMOs) for drug product manufacturing and packaging. This outsourcing model provides flexibility and scalability, especially for its diverse portfolio of rare disease treatments.\u003c\/p\u003e\n\u003cp\u003eEffective supply chain management is paramount for BioMarin, given the specialized nature and global reach of its therapies. Ensuring the consistent and timely delivery of these life-changing treatments to patients worldwide is a critical operational focus, with robust logistics and inventory management systems in place.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Global Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical actively commercializes its approved therapies, with a significant focus on VOXZOGO for achondroplasia. The company is committed to expanding its global reach, ensuring these specialized treatments are accessible to eligible patients worldwide.  This involves robust sales and marketing efforts tailored to diverse healthcare systems and patient populations.\u003c\/p\u003e\n\u003cp\u003eKey activities include developing and executing market access strategies, which are crucial for securing reimbursement and distribution channels in new territories.  For instance, in 2023, BioMarin reported net product revenue of $2.4 billion, with VOXZOGO contributing significantly to this growth, demonstrating the success of its commercialization efforts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Market Expansion:\u003c\/strong\u003e Reaching new patient populations in Europe, Asia, and other key markets for its rare disease therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales and Marketing:\u003c\/strong\u003e Implementing targeted campaigns to educate healthcare professionals and patients about the benefits of approved treatments like VOXZOGO.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Navigating regulatory approvals and reimbursement processes to ensure broad patient access in over 40 countries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Launches:\u003c\/strong\u003e Successfully introducing new indications or formulations of existing products in various international markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Protection and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical's core strategy heavily relies on safeguarding its groundbreaking scientific discoveries. This is primarily achieved through securing and managing patents, which grant exclusive rights to its novel therapies and technologies. This robust intellectual property (IP) portfolio is crucial for maintaining a competitive edge and recouping significant research and development investments.\u003c\/p\u003e\n\u003cp\u003eThe company actively defends its IP rights, demonstrating a commitment to protecting its innovations. For instance, BioMarin has engaged in legal proceedings to address alleged patent infringements by competitors, underscoring the importance of its IP in its business model. This vigilant approach ensures that its market exclusivity for life-changing treatments remains intact.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Filings:\u003c\/strong\u003e BioMarin consistently files new patent applications to protect its pipeline of gene therapies and enzyme replacement therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLitigation:\u003c\/strong\u003e The company has been involved in patent litigation, such as its defense against challenges to its Voydeya patent in 2024, highlighting its proactive IP management.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExclusivity Periods:\u003c\/strong\u003e Patents provide market exclusivity, allowing BioMarin to exclusively commercialize its products for a defined period, critical for revenue generation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePioneering Rare Disease Therapies: From R\u0026amp;D to Global Commercial Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin's key activities center on pioneering research and development for rare genetic diseases, advancing a robust pipeline of therapies, and conducting rigorous clinical trials. The company also focuses on obtaining regulatory approvals and managing manufacturing and supply chains, often using a hybrid model of in-house production and outsourcing. Commercialization of approved treatments, including market access and global expansion, is also a critical ongoing activity.\u003c\/p\u003e\n\u003cp\u003eIn the first quarter of 2024, BioMarin reported research and development expenses of approximately $650 million, showcasing a significant investment in pipeline advancement. The company's net product revenue reached $2.4 billion in 2023, with VOXZOGO being a major contributor, underscoring successful commercialization efforts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eExample\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDiscovering and developing novel therapies for rare genetic diseases.\u003c\/td\u003e\n\u003ctd\u003eQ1 2024 R\u0026amp;D expenses: ~$650 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eEvaluating the safety and efficacy of drug candidates.\u003c\/td\u003e\n\u003ctd\u003eOngoing trials for BMN 351 (DMD) and BMN 333 (skeletal conditions).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring marketing approvals from health authorities.\u003c\/td\u003e\n\u003ctd\u003eTargeting submissions for PALYNZIQ age eligibility expansion in late 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eProducing and distributing therapies globally.\u003c\/td\u003e\n\u003ctd\u003eHybrid model: in-house facilities and CMOs; robust logistics for timely delivery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing and selling approved therapies.\u003c\/td\u003e\n\u003ctd\u003e2023 Net Product Revenue: $2.4 billion; VOXZOGO a key driver.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe BioMarin Pharmaceutical Business Model Canvas you are previewing is the exact document you will receive upon purchase, offering a comprehensive overview of their strategy. This isn't a sample; it's a direct snapshot of the complete canvas, detailing key partners, activities, resources, value propositions, customer relationships, channels, customer segments, cost structure, and revenue streams. Upon completion of your order, you will gain full access to this professionally structured and ready-to-use document.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611153809785,"sku":"biomarin-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomarin-business-model-canvas.png?v=1754751898","url":"https:\/\/growthsharematrix.com\/products\/biomarin-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}